



customised
compounding

Bio-Identical Hormones

—for men & women

- ✓ **a safer¹⁻⁵ HRT option** for the management of menopause, andropause, PCOS, adrenal and immune disorders, reduced libido, and osteoporosis
- ✓ **occur naturally in the human body** and have low cancer risk²⁻⁵, unlike non-naturally occurring (non bio-identical) hormones⁶⁻⁸
- ✓ **no one-size fits all:** patient individualised doses and hormone-combinations are compounded by our pharmacy, based on symptoms and blood results
- ✓ **full-spectrum total HRT:** any combination and concentration of estriol, estradiol, estrone, DHEA, pregnenolone, progesterone & testosterone
- ✓ **effectively delivered** in a highly bio-available^{9,10} transdermal liposomal gel
- ✓ **avoids first pass metabolism**, minimising blood clotting risk^{11,12}

AVAILABLE FROM THE COMPOUNDING PHARMACY OF SOUTH AFRICA

For more information on how to prescribe Bio-Identical Hormones from anywhere in the country, via the Compounding Pharmacy, contact our head pharmacist Wayne Carson at 011 463 0310 or email to pharmacist@compounding.co.za

www.compounding.co.za

References:

1. Husin J.; *Cytological Evaluation of the effect of various estrogens given in post menopause.* Acta Cytologica; 1977; 21:225-228.
2. Campagnoli C.; *Pregnancy, progesterone and progestins in relation to breast cancer risk;* J Steroid Biochem Mol Biol. 2005 Dec;97(5):441-50.
3. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, Baldacci C, Genazzani AR.; *Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells.*; Endocrinology. 2004 Dec; 145(12):5745-56.
4. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P.; *Loss of ERbeta expression as a common step in estrogen-dependent tumor progression;* Endocr Relat Cancer. 2004 Sep; 11(3):537-51.
5. Lemon HM; *Pathophysiologic consideration in the treatment of menopausal patients with estrogens; the role of estriol in the prevention of mammary carcinoma.*; Acta Endocrinol (Copenh); 1980; 223: S17-S27.
6. International Agency for Research on Cancer (IARC) - *Summaries & Evaluations - PROGESTINS (Group 2B) Supplement 7: (1987) (p. 289) -* [<http://www.inchem.org/documents/iarc/suppl7/progestins.html>]
7. J. E. Rossouw et al; *Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial;* Journal of the American Medical Association [JAMA] (2002) Volume 288, pages 321-333.
8. G. L. Anderson et al; *Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.*; Journal of the American Medical Association [JAMA] (2004) Volume 291, pages 1701-1712.
9. Kumar R, Katare OP.; *Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review;* AAPS PharmSciTech. 2005 Oct 6;6(2):E298-310
10. Willmann HL, Luisi PL. *Lecithin organogels as matrix for the transdermal transport of drugs.* Biochem Biophys Res Commun. 1991 Jun 28; 177(3):897-900.
11. Scarabin PY, Oger E, Plu-Bureau G; *Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk;* Lancet. 2003 Aug 9;362(9382):428-32
12. Marianne Canonico et al., *Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women - Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study;* Circulation Feb 2007; 115:840-845).



The Compounding
Pharmacy of SA